特发性炎症性肌病患者的第二原发癌与死亡风险
基于瑞典全国登记数据,纳入1998至2024年诊断的2346例成人特发性炎症性肌病患者,随访至27年。326例在肌病诊断时或之后发生癌症,其中37例发生第二原发癌;男性及有癌症史是第二原发癌的显著危险因素,第二原发癌后三年全因死亡风险为46%,皮肌炎患者死亡风险显著更高。
要点
- 特发性炎症性肌病患者中,男性及有癌症史者第二原发癌风险显著升高。
- 第二原发癌后三年全因死亡风险达46%,皮肌炎亚型死亡风险更高。
- 皮肌炎患者需密切临床监测以降低过早死亡风险。
核心结论
- 特发性炎症性肌病癌症幸存者存在后续癌症负担,皮肌炎患者第二原发癌后死亡风险显著升高,需密切监测。
研究设计与样本
- 基于瑞典全国医疗与人口登记,纳入1998至2024年诊断的2346例≥18岁特发性炎症性肌病患者,随访至27年,采用累积发病率、发病率及柔性参数多状态模型分析。
主要发现
- 326例患者在肌病诊断时或之后发生癌症,其中37例在平均4年随访(最长19年)内发生第二原发癌。
- 第二原发癌整个随访期累积发病率为22%(95%CI 14-33%),而首癌后四年内绝对风险低于5%。
- 男性(HR=3.2,95%CI 1.6-6.5)及有癌症史(HR=3.4,95%CI 1.5-8.0)是第二原发癌的显著危险因素。
- 第二原发癌后三年全因死亡风险为46%(95%CI 44%-70%)。
- 皮肌炎患者第二原发癌后死亡风险显著高于非皮肌炎亚型(HR=3.77,95%CI 1.46-9.75)。
临床怎么用
- 对特发性炎症性肌病患者,尤其男性和有癌症史者,应关注第二原发癌风险。
- 皮肌炎患者发生第二原发癌后需加强监测以降低过早死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the risk of second primary cancer and death in patients who has a cancer diagnosis following idiopathic inflammatory myopathies (IIM). METHODS: Using nationwide Swedish healthcare and population registers, we identified 2346 patients diagnosed with IIM ≥18 years of age between 1998 and 2024. Patients were followed for up to 27 years for first and second post-IIM primary cancers and death. Cumulative incidence function and incidence rate of second primary cancer and death were estimated. A flexible parametric multistate model was used to estimate transition probabilities to cancer and death. Furthermore, risk and prognostic factors for second primary cancer and subsequent death were assessed using multivariable models. RESULTS: Of 326 patients diagnosed with cancer at or after IIM diagnosis, 37 developed a second primary cancer during a mean follow-up of four years (maximum 19 years). The cumulative incidence of second primary cancer over the entire follow-up period was 22% (95% CI 14-33%) while the absolute risk within four years after a first post-IIM cancer was below 5%. Being male (hazard ratio, HR=3.2, 95% CI 1.6-6.5) and having a cancer history (HR=3.4, 95% CI 1.5-8.0) were significant risk factors of second primary cancers. The three-year all-cause mortality risk after a second primary cancer was 46% (95% CI 44%-70%). Patients with dermatomyositis had a markedly elevated mortality risk following a second primary cancer diagnosis compared to non-dermatomyositis subtypes (HR=3.77, 95% CI 1.46-9.75). CONCLUSION: These findings provide new insight into the burden of subsequent cancers among IIM cancer survivors and highlight the need for close clinical monitoring for patients with dermatomyositis to reduce premature mortality.
引用
- Che WI, Baecklund F, Kuja-Halkola R, et al. Risk of second primary cancer and death in patients with idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2026. PMID: 42140175. doi:10.1016/j.semarthrit.2026.152997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。